Intellectus Partners LLC grew its stake in Illumina, Inc. (NASDAQ:ILMN) by 26.6% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 10,077 shares of the life sciences company’s stock after purchasing an additional 2,117 shares during the period. Illumina accounts for 1.4% of Intellectus Partners LLC’s portfolio, making the stock its 16th biggest position. Intellectus Partners LLC’s holdings in Illumina were worth $3,343,000 as of its most recent SEC filing.
Other institutional investors also recently modified their holdings of the company. Kornitzer Capital Management Inc. KS boosted its holdings in shares of Illumina by 20.4% in the 3rd quarter. Kornitzer Capital Management Inc. KS now owns 104,845 shares of the life sciences company’s stock valued at $31,896,000 after buying an additional 17,796 shares in the last quarter. Integrated Wealth Concepts LLC boosted its holdings in shares of Illumina by 23.4% in the 3rd quarter. Integrated Wealth Concepts LLC now owns 1,278 shares of the life sciences company’s stock valued at $389,000 after buying an additional 242 shares in the last quarter. Sterling Investment Advisors Ltd. boosted its holdings in shares of Illumina by 14.6% in the 3rd quarter. Sterling Investment Advisors Ltd. now owns 2,165 shares of the life sciences company’s stock valued at $659,000 after buying an additional 275 shares in the last quarter. Keudell Morrison Wealth Management acquired a new position in shares of Illumina in the 2nd quarter valued at $1,483,000. Finally, Sunbelt Securities Inc. boosted its holdings in shares of Illumina by 130.9% in the 3rd quarter. Sunbelt Securities Inc. now owns 1,443 shares of the life sciences company’s stock valued at $438,000 after buying an additional 818 shares in the last quarter. Institutional investors and hedge funds own 91.77% of the company’s stock.
Several research analysts have recently issued reports on ILMN shares. ValuEngine cut shares of Illumina from a “buy” rating to a “hold” rating in a report on Friday, December 20th. Guggenheim started coverage on shares of Illumina in a report on Friday, October 25th. They issued a “buy” rating and a $350.00 target price for the company. Cowen restated an “outperform” rating and issued a $335.00 target price (up previously from $320.00) on shares of Illumina in a report on Wednesday, December 18th. Citigroup assumed coverage on shares of Illumina in a research note on Monday, January 6th. They set a “buy” rating and a $385.00 price target for the company. Finally, Piper Sandler increased their price target on shares of Illumina from $341.00 to $370.00 and gave the stock an “overweight” rating in a research note on Thursday, January 9th. Three investment analysts have rated the stock with a sell rating, three have issued a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. Illumina has a consensus rating of “Buy” and an average target price of $339.81.
Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, October 24th. The life sciences company reported $1.93 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.40 by $0.53. The firm had revenue of $907.00 million during the quarter, compared to analysts’ expectations of $872.65 million. Illumina had a net margin of 28.14% and a return on equity of 22.05%. Illumina’s quarterly revenue was up 6.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.52 EPS. Research analysts forecast that Illumina, Inc. will post 6.46 EPS for the current fiscal year.
In other Illumina news, SVP Phillip G. Febbo sold 155 shares of the company’s stock in a transaction on Thursday, November 14th. The shares were sold at an average price of $300.00, for a total transaction of $46,500.00. Following the completion of the transaction, the senior vice president now owns 1,506 shares in the company, valued at approximately $451,800. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Charles Dadswell sold 193 shares of the company’s stock in a transaction on Friday, November 1st. The stock was sold at an average price of $297.28, for a total transaction of $57,375.04. Following the transaction, the senior vice president now owns 5,069 shares of the company’s stock, valued at approximately $1,506,912.32. The disclosure for this sale can be found here. In the last quarter, insiders have sold 3,920 shares of company stock valued at $1,262,212. 0.38% of the stock is owned by company insiders.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
See Also: Analyst Ratings Trading
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.